NASDAQ · CVAC
Healthcare · Biotechnology
$4.66
Up+$0.00 (+0.00%)
Updated Sep 9, 2026, 1:24 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CVAC does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CVAC.
CVAC research
Company profile and research snapshot.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 26, 2025 | UBS | Neutral | — |
| Jun 13, 2025 | Jefferies | Hold | — |
| May 28, 2025 | JMP Securities | Market Outperform | — |
| Apr 30, 2025 | UBS | Buy | — |
| Feb 14, 2025 | JMP Securities | Market Outperform | — |
No generated briefing is available yet.
Benzinga · Dec 3, 2025
BioNTech successfully met the minimum condition for its exchange offer to acquire CureVac, with 81.74% of CureVac shares tendered. The subsequent offering period will continue until December 18, 2025, allowing remaining shareholders to participate.
seekingalpha.com · Nov 28, 2025
CureVac N.V. ( CVAC ) Shareholder/Analyst Call November 25, 2025 8:00 AM EST Company Participants Mehdi Shahidi Marco Rau Thaminda Ramanayake - Chief Business Officer & Member of Executive Board Alexander Zehnder - CEO, MD & Member of Management Board Presentation Mehdi Shahidi Welcome, everyone, to this Extraordinary General Meeting of Shareholders of CureVac N.V.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CVAC.
No results
No recent SID articles mention CVAC.
